Mode
Text Size
Log in / Sign up

Radiomics models show moderate accuracy for predicting microsatellite instability status in gastric cancer patientsImaging data helps predict specific markers in gastric cancer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that radiomics provides moderate accuracy for preoperative MSI prediction, with combined clinical models improving specificity.

This meta-analysis evaluates the diagnostic performance of radiomics for predicting microsatellite instability (MSI) status in patients with gastric cancer. The analysis included a total sample size of 2447 patients to assess how radiomics features compare against logistic regression and combined models incorporating clinical data.

The findings indicate that radiomics models achieved a validation set AUC of 0.82 (95% CI: 0.79-0.85) with a sensitivity of 0.79 (95% CI: 0.73-0.84) and specificity of 0.72 (95% CI: 0.67-0.76). While the training set AUC was higher at 0.88, the results for internal and external validation were comparable at 0.82 and 0.83 respectively. Notably, machine learning did not outperform logistic regression in this context.

Combined models incorporating clinical features showed improved specificity of 0.75 compared to radiomics-only models (0.68). The authors note that the difference between training and validation performance highlights a need for more rigorous external validation. Radiomics currently offers moderate diagnostic accuracy for preoperative MSI prediction, potentially aiding in patient selection for targeted therapies.

How this fits prior evidence

This meta-analysis addresses a gap in identifying patients suitable for immunotherapy by evaluating radiomics as a tool to predict microsatellite instability (MSI) status. While previous evidence has identified factors like spatial immune niches and metabolic reprogramming that drive immunotherapy resistance in gastric cancer, this study focuses on the diagnostic utility of imaging features to identify specific biomarkers like MSI.

When patients are diagnosed with gastric cancer, knowing their microsatellite instability (MSI) status is vital for choosing the right treatment. Currently, identifying this status often happens after surgery. However, researchers analyzed data from over 2,400 patients to see if radiomics—a method of extracting large amounts of data from medical images—could predict this status earlier.

The study found that these imaging models have moderate accuracy in predicting MSI before surgery. While the technology shows promise, it did not perform better than standard logistic regression methods. However, combining these image features with clinical information improved the specificity of the results, which helps doctors better select the right patients for specific therapies.

Because there were differences between how the models performed during training and during validation, researchers note that more rigorous testing is still needed. While radiomics is a helpful tool for prediction, it is not meant to replace the careful judgment of a clinical team.

What this means for you:
Imaging data can help predict cancer markers before surgery, especially when combined with patient clinical details.

Common questions

What is radiomics and how does it help with cancer?

Radiomics is a way of pulling large amounts of data from medical images, like CT scans. In this study, it was used to predict microsatellite instability (MSI) in patients with gastric cancer. It helps doctors identify specific markers before surgery, which can help them choose the best treatment plan for each individual patient.

How accurate is this imaging method for predicting results?

The study showed that radiomics has moderate diagnostic accuracy. In a validation set, it achieved an area under the curve (AUC) of 0.82. While machine learning did not outperform standard logistic regression methods, combining image data with clinical features improved the specificity of the prediction.

Is this method ready to replace current doctor assessments?

No, radiomics is not a replacement for clinical assessment by doctors. The study noted that while these tools provide helpful information for patient selection, the results are still subject to some uncertainty because of differences in how models performed during training versus validation.

Study Details

Study typeMeta analysis
Sample sizen = 2,447
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Microsatellite instability (MSI) is a key biomarker for immunotherapy in gastric cancer (GC), but preoperative non-invasive prediction remains challenging. Radiomics is promising; however, a systematic evaluation of its diagnostic performance with explicit consideration of overfitting and model comparison is lacking. METHODS: We systematically searched PubMed, Embase, Web of Science, and Cochrane Library up to March 25, 2026, for studies on radiomics for preoperative MSI prediction in GC. A bivariate random-effects model pooled sensitivity, specificity, and diagnostic odds ratio (DOR). Subgroup analyses were performed by model type, data source, validation type, and algorithm. RESULTS: Thirteen studies (2,447 patients) were included. In validation sets (17 data points), the pooled AUC was 0.82 (95% CI: 0.79-0.85), sensitivity 0.79 (95% CI: 0.73-0.84), and specificity 0.72 (95% CI: 0.67-0.76). Performance was higher in training sets (AUC 0.88). Combined models (radiomics plus clinical features) achieved higher specificity than radiomics models (0.75 vs. 0.68) in validation sets. Externally and internally validated models had comparable AUC (0.82 vs. 0.83). Machine learning did not outperform logistic regression. CONCLUSION: radiomics demonstrates moderate diagnostic accuracy for preoperative MSI prediction in GC. Combined models improve specificity, aiding patient selection. Differences between training and validation performance underscore the need for rigorous external validation. Prospective, multicenter studies are warranted. REGISTRATION: This research was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was prospectively registered with the PROSPERO database under registration number CRD420251148467. The protocol is available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251148467 .
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.